Kelun-Biotech's Sac-TMT Targets First-Line TNBC Treatment as NMPA Accepts New Indication Application
Event summary
- Kelun-Biotech's sacituzumab tirumotecan (sac-TMT) application for first-line treatment of advanced TNBC accepted by NMPA for review on July 30, 2026.
- Application based on positive Phase III OptiTROP-Breast03 study results showing statistically significant efficacy improvements over chemotherapy.
- This marks the sixth indication application accepted by NMPA for sac-TMT, with priority review status expected to expedite approval.
- Sac-TMT previously granted Breakthrough Therapy Designation (BTD) by NMPA for this indication.
The big picture
This development positions sac-TMT as a potential first-line treatment option for advanced TNBC patients with PD-L1 CPS <10, addressing an unmet clinical need. The priority review status underscores the drug's strategic importance in Kelun-Biotech's portfolio and its potential to capture significant market share in oncology. With MSD leading global studies, sac-TMT could become a key player in the international ADC market.
What we're watching
- Regulatory Momentum
- Whether the priority review status will lead to accelerated approval and commercialization of sac-TMT for this new indication.
- Market Expansion
- How successful global Phase III studies led by MSD could expand sac-TMT's market reach beyond Greater China.
- Competitive Positioning
- The pace at which Kelun-Biotech can leverage this approval to strengthen its leadership in TROP2-directed ADCs against competitors.